In general, breast cancer patients that were alive at follow‐up had lower median methylation of RASSF1‐1α, in agreement with the tumor suppressor role of RASSF1A, than those stages I and II patients that had died of breast cancer (Appendix Fig S3B). The gene discussed is RASSF1; the disease is neoplasm.